0.90Open1.04Pre Close1.44K Volume2.06K Open Interest5.00Strike Price121.92KTurnover229.31%IV32.08%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.85Extrinsic Value100Contract SizeAmericanOptions Type-0.2613Delta0.0882Gamma7.41Leverage Ratio-0.0236Theta-0.0015Rho-1.94Eff Leverage0.0052Vega
Sana Biotechnology Stock Discussion
• Editing Genes | $CRISPR Therapeutics(CRSP.US)$ , $Intellia Therapeutics(NTLA.US)$ , $Beam Therapeutics(BEAM.US)$ , $Verve Therapeutics(VERV.US)$ , $Editas Medicine(EDIT.US)$
• Creating Therapies | $Prime Medicine(PRME.US)$ , $Sana Biotechnology(SANA.US)$
• Building DNA | $Twist Bioscience(TWST.US)$ , $Ginkgo Bioworks(DNA.US)$ , $Pacific Biosciences of California(PACB.US)$ , $Illumina(ILMN.US)$
• Dis...
• $Repare Therapeutics(RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US)$ +10.2% (In reaction ...
SANA announced an initial payment of 50M using Beam's Cas12b system.
It's great for Beam that Cas12b, which Beam doesn't use, is being asked for. The strangest thing is that SANA only needs Cas12b, not Base Editor. It's hard to understand! ?
No comment yet